We are live on ! Find out more
PRQR icon

ProQR Therapeutics

46 hedge funds and large institutions have $60M invested in ProQR Therapeutics in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 9 increasing their positions, 14 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

278% more capital invested

Capital invested by funds: $15.9M → $60M (+$44.1M)

7% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 15

2% less funds holding

Funds holding: 4746 (-1)

6.4% less ownership

Funds ownership: 29.8%23.4% (-6.4%)

12% less call options, than puts

Call options by funds: $655K | Put options by funds: $746K

36% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 14

Holders
46
Holders Change
-1
Holders Change %
-2.13%
% of All Funds
0.74%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
14
Increased
9
Reduced
14
Closed
15
Calls
$655K
Puts
$746K
Net Calls
-$91K
Net Calls Change
-$131K
Name Holding Trade Value Shares
Change
Change in
Stake
Goldman Sachs
51
Goldman Sachs
New York
-$117K -157,910 Closed
AC
52
Apogem Capital
New York
-$93K -124,424 Closed
Group One Trading
53
Group One Trading
Illinois
-$53.9K -41,126 Closed
Balyasny Asset Management
54
Balyasny Asset Management
Illinois
-$16K -21,433 Closed
BCM
55
Bayesian Capital Management
New York
-$10K -13,400 Closed
AG
56
Algert Global
California
-$8K -10,665 Closed
AIM
57
Axiom Investment Management
New York
-$3K -4,500 Closed
Zurich Cantonal Bank
58
Zurich Cantonal Bank
Switzerland
-$3K -3,819 Closed
BHWM
59
Beaird Harris Wealth Management
Texas
-$1K -999 Closed
CUAMC
60
China Universal Asset Management Company
China
-$1K -701 Closed

PRQR Hedge Fund Activity: Q4 2022 in Review

46 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2022, worth a combined $60M — up 278% from $15.9M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of PRQR and 14 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 9 added.

The largest buyer was M28 Capital Management, adding an estimated $1.19M. The largest seller was Opaleye Management, cutting an estimated $2.17M.

  • 46 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2022, down from 47 in Q3 2022.
  • Funds reported $60M of ProQR Therapeutics stock for Q4 2022, up 278% quarter-over-quarter.
  • 14 funds opened new ProQR Therapeutics positions in Q4 2022 and 15 closed out, a net change of -1 holder.
  • The largest ProQR Therapeutics buyer in Q4 2022 was M28 Capital Management, an estimated $1.19M added.
  • The largest ProQR Therapeutics seller in Q4 2022 was Opaleye Management, an estimated $2.17M sold.

Based on aggregated 13F filings for Q4 2022.